We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > pom-dex

News List

Sanofi's Sarclisa bags NICE recommendation pharmatimes
October 19, 2020
French pharma Sanofi’s Sarclisa has been granted a positive recommendation from the National Institute for Health and Care (NICE) for patients with multiple myeloma.
NICE rejects Sanofi's Sarclisa in preliminary guidelines pharmatimes
June 09, 2020
NICE has published initial guidelines rejecting NHS use of a therapy combination containing Sanofi's Sarclisa (isatuximab) to treat multiple myeloma.
Sanofi secures EC approval for Sarclisa for third-line multiple myeloma pharmaceutical-business-review
June 08, 2020
Sanofi has secured approval from the European Commission (EC) for Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of relapsed and refractory multiple myeloma (MM) in adult patients.